Applying New Stem Cell Science to Reboot the Immune System


Magenta Therapeutics is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients.


Year Invested: 2016
Location: Cambridge, Mass.
Visit: www.magentatx.com

Recent News

April 9, 2018
Magenta Therapeutics Secures $52 Million in Series C Financing

April 5, 2018
Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders

April 3, 2018
Magenta Therapeutics Announces Departure of Chief Operating Officer Bastiano Sanna, Ph.D.

Read More News

Associated Team Members

Alexis Borisy
Partner

Stephen Sherwin, M.D.
Venture Partner